DC JimTash is also wrong about Patents...Provista Diagnostics and AMDL Diagnostics have an agreement. It is a 5 Year exclusive agreement. It allows Provista to combine DR-70 with their IP to improve the BT Test for Breast, Colon, Lung, Ovarian..The LC Sentinel Lung Cancer Test is owned by Radient and Provista..It is being used for GCDX/Provista Lung Cancer Test from the agreement with Radient and GCDX.. This is the reason Provista/GCDX? Radient are remaining silet about the use of DR-70, because it is now off patent..Once Provista/GCDX get FDA approved with the New Generation test combining DR-70 with the ASU reagents, they can get FDA approved. The ASU IP are patented...Dr-70 can be used by anyone, bit according to our illusinists, it is not accurate as a stand alone..Who in their right mind would want it? Provista wants it and the angel investors... It improved their Lung and Breast cancer tests along with the other Tests in the pipeline, such as Ovarian, Endo, and new generation DR-70 Colon test...imo
dcspka Thursday, 03/26/15 10:46:38 AM
Re: livinginsv post# 28507
Post # of 28512
Living you are putting the wrong financial slant on your overall outlook concerning DR-70/Onko-Sure.
"DR-70 can detect 19 different types of cancer, that is the benefit of DR-70..Combined with Provista's IP it is a better test in all 19...Now Provista can get the New Generation test FDA approved more quickly...We are sitting on a "Diamond In The Rough" You understand....Wolf"
